Publicaciones en las que colabora con Eduardo Carlos Salido Ruiz (10)

2023

  1. Determinants of Kidney Failure in Primary Hyperoxaluria Type 1: Findings of the European Hyperoxaluria Consortium

    Kidney International Reports, Vol. 8, Núm. 10, pp. 2029-2042

2022

  1. New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production

    European Journal of Medicinal Chemistry, Vol. 237

2019

  1. Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1

    Nucleic Acid Therapeutics, Vol. 29, Núm. 2, pp. 104-113

2018

  1. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

    Nature Communications, Vol. 9, Núm. 1

  2. Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1

    Journal of Medicinal Chemistry, Vol. 61, Núm. 16, pp. 7144-7167

  3. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria

    Molecular Therapy, Vol. 26, Núm. 8, pp. 1983-1995

2017

  1. Molecular therapy of primary hyperoxaluria

    Journal of Inherited Metabolic Disease, Vol. 40, Núm. 4, pp. 481-489

  2. siRNA therapeutics to treat liver disorders

    Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders (Springer International Publishing), pp. 159-190

2016

  1. Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of primary hyperoxaluria Type I

    Molecular Therapy, Vol. 24, Núm. 4, pp. 719-725

  2. Iohexol plasma clearance, a simple and reliable method to measure renal function in conscious mice

    Pflugers Archiv European Journal of Physiology, Vol. 468, Núm. 9, pp. 1587-1594